Tumour Selective Activation of Rotaxanated DNA-fork-binding Metallo-supramolecular Nano-cylinder Helicates

Rotaxanated DNA 叉结合金属超分子纳米圆柱螺旋的肿瘤选择性激活

• 批准号: EP/X02282X/1
• 负责人: Michael Hannon
• 金额: $ 26万
• 依托单位: University of Birmingham
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FX02282X%2F1
• 关键词: Tumour; Selective; Activation; Rotaxanated; DNA

This proposal will develop at Birmingham a highly promising early career researcher, Dr Subhendu Karmakar, who has previous experience and skills from top labs in Jerusalem and India. He will gain advanced training at the interface of supramolecular and bioinorganic chemistry with biology, under the supervision of a leading bioinorganic chemist, Mike Hannon, that will develop him to a position where he will be ready to secure an academic position to launch his own independent research career in Bioinorganic Chemistry, supported by and further developing the European links and collaborations he will have formed. Alongside the new techniques and approaches in non-covalent DNA-binding and metallo-supramolecular and rotaxane drug designs, and the transferable skills training he will gain, he will transfer to Birmingham his expertise in activation of drugs in hypoxic tisues, enhancing the capabilities of the Birmingham team and enabling an exciting new project made possible only by interfacing their respective skill bases. The result will be a powerful and innovative new approach to agents that will bind and interfere with critical DNA fork structures essential to cancer cell replication and which will do so only in cancer cells and so minimise collateral damage to normal tissue and thus side-effects. The project will reveal and enable new horizons for metallo-supramolecular drug design and transform the state-of-the-art for metallo-therapeutics.

这项提议将在伯明翰培养一位非常有前途的早期职业研究人员Subhendu Karmakar博士，他之前在耶路撒冷和印度的顶级实验室拥有经验和技能。他将在领先的生物无机化学家迈克·汉农的指导下，在超分子和生物无机化学与生物学的接口上接受高级培训，这将使他发展到一个位置，在他将形成的欧洲联系和合作的支持和进一步发展的支持下，他将准备好获得一个学术职位，开始他自己在生物无机化学领域的独立研究事业。除了在非共价DNA结合和金属超分子和轮烷药物设计方面的新技术和方法，以及他将获得的可转移技能培训外，他还将向伯明翰转移他在缺氧组织中激活药物的专业知识，增强伯明翰团队的能力，并实现一个只有通过连接他们各自的技能基础才能实现的令人兴奋的新项目。其结果将是一种强大而创新的新方法，这些药物将结合和干扰对癌细胞复制至关重要的关键DNA分叉结构，并且仅在癌细胞中这样做，从而将对正常组织的附带损害降至最低，从而将副作用降至最低。该项目将揭示和实现金属超分子药物设计的新视野，并改变金属治疗的最新水平。